Université de Montpellier. centre hospitalier universitaire de Montpellier
Adresse e-mail validée de
Citée par
Citée par
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ...
N Engl j Med 371, 2167-2177, 2014
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter …
T Le Chevalier, D Brisgand, JY Douillard, JL Pujol, V Alberola, A Monnier, ...
Journal of Clinical Oncology 12 (2), 360-367, 1994
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
F Barlesi, J Mazieres, JP Merlio, D Debieuvre, J Mosser, H Lena, ...
The Lancet 387 (10026), 1415-1426, 2016
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non …
L Paz-Ares, F de Marinis, M Dediu, M Thomas, JL Pujol, P Bidoli, ...
The lancet oncology 13 (3), 247-255, 2012
PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin …
LG Paz-Ares, F de Marinis, M Dediu, M Thomas, JL Pujol, P Bidoli, ...
Journal of clinical oncology 31 (23), 2895-2902, 2013
Cisplatin-based adjuvant chemotherapy in patients with completely resected non–small-cell lung cancer
International Adjuvant Lung Cancer Trial Collaborative Group
New England Journal of Medicine 350 (4), 351-360, 2004
Survival of patients with resected N2 non–small-cell lung cancer: evidence for a subclassification and implications
F Andre, D Grunenwald, JP Pignon, A Dujon, JL Pujol, PY Brichon, ...
Journal of clinical oncology 18 (16), 2981-2989, 2000
Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer
JL Pujol, J Grenier, JP Daurès, A Daver, H Pujol, FB Michel
Cancer research 53 (1), 61-66, 1993
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix, L Paz-Ares, CH Chiu, ...
The Lancet Oncology 20 (12), 1655-1669, 2019
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind …
JF Vansteenkiste, BC Cho, T Vanakesa, T De Pas, M Zielinski, MS Kim, ...
The lancet oncology 17 (6), 822-835, 2016
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
JR Eckardt, J von Pawel, JL Pujol, Z Papai, E Quoix, A Ardizzoni, R Poulin, ...
Journal of Clinical Oncology 25 (15), 2086-2092, 2007
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
T Le Chevalier, G Scagliotti, R Natale, S Danson, R Rosell, R Stahel, ...
Lung cancer 47 (1), 69-80, 2005
Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this …
JL Pujol, JP Daurès
British journal of cancer 83 (1), 8-15, 2000
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer
JC Soria, Z Márk, P Zatloukal, B Szima, I Albert, E Juhász, JL Pujol, ...
J Clin Oncol 29 (33), 4442-4451, 2011
Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer
J von Pawel, U Gatzemeier, JL Pujol, L Moreau, S Bildat, M Ranson, ...
Journal of clinical oncology 19 (6), 1743-1749, 2001
CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients
JL Pujol, O Molinier, W Ebert, JP Daures, F Barlesi, G Buccheri, ...
British Journal of Cancer 90 (11), 2097-2105, 2004
Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients
JL Pujol, JM Boher, J Grenier, X Quantin
Lung cancer 31 (2-3), 221-231, 2001
Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours
W Jacot, D Bessis, E Jorda, M Ychou, M Fabbro, JL Pujol, B Guillot
British Journal of Dermatology 151 (1), 238-241, 2004
Carcinoid tumors of the lung: do atypical features require aggressive management?
CH Marty-Ané, V Costes, JL Pujol, M Alauzen, P Baldet, H Mary
The Annals of thoracic surgery 59 (1), 78-83, 1995
A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index
B Colinet, W Jacot, D Bertrand, S Lacombe, MC Bozonnat, JP Daures, ...
British journal of cancer 93 (10), 1098-1105, 2005
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20